問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Urology

Division of Hematology & Oncology

Division of Radiation Therapy

China Medical University Hospital-Taipei (在職)

Division of Urology

更新時間：2023-09-19

張兆祥Chang, Chao-Hsiang
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

47Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張兆祥

List

88Cases

2017-06-15 - 2025-12-31

Phase III

Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

  • Condition/Disease

    Metastatic Castrate-Resistant Prostate Cancer

  • Test Drug

    IPATASERTIB

Participate Sites
6Sites

Terminated4Sites

林永昌
Linkou Chang Gung Medical Foundation

黃書彬
Kaohsiung Municipal Gangshan Hospital

未分科

2013-09-01 - 2024-03-31

Phase III

Completed
PROSPER: A Multinational, Phase 3, Randomized, Double‑Blind, Placebo‑Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration‑Resistant Prostate Cancer

  • Condition/Disease

    Nonmetastatic Castration Resistant Prostate Cancer

  • Test Drug

    Enzalutamide

Participate Sites
11Sites

Terminated11Sites

2021-01-04 - 2026-04-30

Phase III

Active
A Phase 3 Study of CG0070 in Patients with Non-Muscular Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)

  • Condition/Disease

    This is a Phase 3, open-label, trial designed to evaluate CG0070 in patients with high-grade CIS of the bladder unresponsive to Bacillus Calmette-Guerin (BCG).

  • Test Drug

    CG0070 DDM

Participate Sites
4Sites

Recruiting4Sites

2022-07-01 - 2027-12-31

Phase III

Active
Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.

  • Condition/Disease

    Advanced Malignancies NS

  • Test Drug

    Avelumab (MSB0010718C)PF-04518600 (OX-40)Utomilumab (PF-05082566)

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2023-03-20 - 2030-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2015-12-01 - 2028-12-29

Phase III

Active
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy

  • Condition/Disease

    Advanced Prostate Cancer

  • Test Drug

    JNJ-56021927

Participate Sites
7Sites

Terminated6Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2020-10-26 - 2028-06-30

Phase III

Active
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

  • Condition/Disease

    Metastatic Castration-Sensitive Prostate Cancer

  • Test Drug

    Niraparib

Participate Sites
9Sites

Not yet recruiting1Sites

Recruiting1Sites

Terminated7Sites

2019-07-22 - 2026-12-29

Phase III

Active
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy

  • Condition/Disease

    Advanced Prostate Cancer

  • Test Drug

    Apalutamide (JNJ-56021927)

Participate Sites
7Sites

Recruiting7Sites

2025-11-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-01-01 - 2029-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

1 2 3 4 5 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB